Topical delivery of 4-hexylresorcinol promotes wound healing via tumor necrosis factor-α suppression

J Korean Assoc Oral Maxillofac Surg

2016

Self Cite

Mucoepidermoid carcinoma (MEC) is the most common type of malignant neoplasm in the minor salivary gland. The hard palate is a frequently involved site of MEC. The treatment of low-grade MEC on the hard palate is wide local resection with a tumor-free margin. In the present case, the maxillary defect was reconstructed using a buccal fat pad (BFP) flap, followed by application of 4-hexylresorcinol (4HR) ointment for 2 weeks. The grafted BFP successfully covered the tumor resection defect without tension and demonstrated complete re-epithelialization without any complications.

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reconstruction of partial maxillectomy defect with a buccal fat pad flap and application of 4-hexylresorcinol: a case report

Seok

J Korean Assoc Oral Maxillofac Surg

2016

Self Cite

“…The 4-HR compound inhibits foreign-body giant cell formation via suppression of the diacylglycerol kinase in macrophages, and induces the biodegradation of the graft material [31,34]. Thus, 4-HR is associated with soft-tissue healing and regeneration [56]. Furthermore, it inhibits tumor necrosis factor-α (TNF-α) expression in raw cells, and contributes to the rapid epithelization and collagen regeneration in burn wounds [56].…”

Section: Discussionmentioning

confidence: 99%

Angioplasty Using 4-Hexylresorcinol-Incorporated Silk Vascular Patch in Rat Carotid Defect Model

et al. 2018

Applied Sciences

Self Cite

The aim of this study was to evaluate and compare the efficacy of 4-hexylresorcinol (4-HR)-incorporated silk as a vascular patch scaffold to that of the commercial polytetrafluoroethylene (PTFE) vascular patch (GORE® ACUSEAL). The expression of the vascular endothelial cell growth factor-A (VEGF-A) after application of 4-HR was studied in RAW264.7 and HUVEC cells. In the animal study, a carotid artery defect was modeled in Sprague Dawley rats (n = 30). The defect was directly closed in the control group (n = 10), or repaired with the PTFE or 4-HR silk patch in the experimental groups (n = 10 per group). Following patch angioplasty, angiography was performed and the peak systolic velocity (PSV) was measured to evaluate the artery patency. The application of 4-HR was shown to increase the expression of VEGF-A in RAW264.7 and HUVEC cells. The successful artery patency rate was 80% for the 4-HR silk group, 30% for the PTFE group, and 60% for the control group. The PSV of the 4-HR silk group was significantly different from that of the control group at one week and three weeks post-angioplasty (p = 0.005 and 0.024). Histological examination revealed new regeneration of the arterial wall, and that the arterial diameter was well maintained in the 4-HR silk group in the absence of an immune reaction. In contrast, an overgrowth of endothelium was observed in the PTFE group. In this study, the 4-HR silk patch was successfully used as a vascular patch, and achieved a higher vessel patency rate and lower PSV than the PTFE patch.

“…Any inducer of M2-type macrophages is considered to be beneficial for graft success [75]. 4HR inhibits the NF-κB pathway [76] and the expression of TNF-α [77]. Accordingly, 4HR-induced M2-type macrophages have M2d characteristics except for TNF-α expression.…”

Section: -Hexylresorcinol For the Immunomodulationmentioning

confidence: 99%

Immunomodulation for maxillofacial reconstructive surgery

Maxillofac Plast Reconstr Surg

2020

Self Cite

Immunomodulation is a technique for the modulation of immune responses against graft material to improve surgical success rates. The main target cell for the immunomodulation is a macrophage because it is the reaction site of the graft and controls the healing process. Macrophages can be classified into M1 and M2 types. Most immunomodulation techniques focus on the rapid differentiation of M2-type macrophage. An M2 inducer, 4-hexylresorcinol, has been recently identified and is used for bone grafts and dental implant coatings.